Chen Huimin, Li Hongfen, Liu Zhanju
Department of Pediatrics, Jiaozuo Women and Children Hospital, Jiaozuo, China.
Department of Gastroenterology, The Shanghai Tenth People's Hospital of Tongji University, No. 301 Yanchang Road, Shanghai, 200072, China.
Therap Adv Gastroenterol. 2020 Sep 9;13:1756284820935188. doi: 10.1177/1756284820935188. eCollection 2020.
Inflammatory bowel diseases (IBDs), including ulcerative colitis and Crohn's disease, are chronic inflammatory disorders of the gastrointestinal tract. With in-depth studies on the mechanisms of the initiation and development of IBD, increasing lines of evidence have focused on the intestinal microbiota in the pathogenesis of IBD. The imbalance between the host and intestinal microbiota induces dysregulated immune response in intestinal mucosa and plays a pivotal role in the initiation of disease and ongoing bowel destruction. This review focuses on recent advances in intestinal microbiota regulation of mucosal immune response as well as novel approaches based on intestinal microbiota alterations in the diagnosis and evaluation of therapeutic response in IBD.
炎症性肠病（IBDs），包括溃疡性结肠炎和克罗恩病，是胃肠道的慢性炎症性疾病。随着对IBD起始和发展机制的深入研究，越来越多的证据聚焦于肠道微生物群在IBD发病机制中的作用。宿主与肠道微生物群之间的失衡会导致肠道黏膜免疫反应失调，并在疾病的起始和持续的肠道破坏中起关键作用。本综述重点关注肠道微生物群对黏膜免疫反应调节的最新进展，以及基于肠道微生物群改变的IBD诊断和治疗反应评估的新方法。
Zotero 插件